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BACKGROUND
Sickle cell anemia is an inherited blood disorder that is characterized by painful 
vaso-occlusive crises, for which there are few treatment options. Platelets mediate 
intercellular adhesion and thrombosis during vaso-occlusion in sickle cell anemia, 
which suggests a role for antiplatelet agents in modifying disease events.
METHODS
Children and adolescents 2 through 17 years of age with sickle cell anemia were 
randomly assigned to receive oral prasugrel or placebo for 9 to 24 months. The pri-
mary end point was the rate of vaso-occlusive crisis, a composite of painful crisis or 
acute chest syndrome. The secondary end points were the rate of sickle cell–related 
pain and the intensity of pain, which were assessed daily with the use of pain diaries.
RESULTS
A total of 341 patients underwent randomization at 51 sites in 13 countries across 
the Americas, Europe, Asia, and Africa. The rate of vaso-occlusive crisis events per 
person-year was 2.30 in the prasugrel group and 2.77 in the placebo group (rate 
ratio, 0.83; 95% confidence interval, 0.66 to 1.05; P = 0.12). There were no signifi-
cant differences between the groups in the secondary end points of diary-reported 
events. The safety end points, including the frequency of bleeding events requiring 
medical intervention, of hemorrhagic and nonhemorrhagic adverse events that oc-
curred while patients were taking prasugrel or placebo, and of discontinuations 
due to prasugrel or placebo, did not differ significantly between the groups.
CONCLUSIONS
Among children and adolescents with sickle cell anemia, the rate of vaso-occlusive 
crisis was not significantly lower among those who received prasugrel than among 
those who received placebo. There were no significant between-group differences 
in the safety findings. (Funded by Daiichi Sankyo and Eli Lilly; ClinicalTrials.gov 
number, NCT01794000.)
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Sickle cell anemia, which is estimat-ed to affect 100 million persons world-wide, is an inherited blood disorder char-
acterized by hemolytic anemia and recurrent 
vaso-occlusive crises that are associated with 
hospitalizations, impaired quality of life, and 
early death.1-3 The pathophysiological mechanism 
of vaso-occlusion in sickle cell anemia is complex. 
The polymerization of sickle hemoglobin initiates 
a cascade of thrombotic and inflammatory in-
sults that result in progressive vascular damage 
and ischemic end-organ injury.4 Hydroxyurea is 
partially effective in reducing the frequency of 
acute vaso-occlusive events, but it has not been 
shown to prevent organ damage.5 There is an 
unmet need for additional agents that target the 
pathophysiological basis of the disease.6
Platelets play a role in the pathogenesis of 
sickle cell disease. Induced in part by adenosine 
diphosphate (ADP) released by lysed erythrocytes, 
activated platelets mediate the formation of mul-
ticellular aggregates and promote inflammation 
during vaso-occlusion.7-10 Abnormalities in plate-
let count, turnover, and survival, as well as mark-
ers of platelet activation, are found at steady state 
and are exacerbated during vaso-occlusive cri-
ses.11-13 Several studies have suggested a benefit 
of ADP-directed antiplatelet therapy in reducing 
markers of platelet activation, as well as the rate 
and intensity of pain in patients with sickle cell 
disease.14,15
Prasugrel is an oral, third-generation thieno-
pyridine that inhibits ADP-mediated platelet ac-
tivation and aggregation by irreversibly binding 
to the P2Y12 class of ADP receptors.11,16 Previous 
studies involving patients with sickle cell disease 
who were treated with prasugrel documented 
levels of platelet inhibition similar to those in 
healthy persons,17 as well as reductions in platelet 
activation and in vaso-occlusive pain18; the studies 
also established the basis for a dose-adjustment 
strategy for the treatment of children with sickle 
cell anemia.19 Together, these studies provided the 
rationale for the Determining Effects of Platelet 
Inhibition on Vaso-Occlusive Events (DOVE) trial.
Me thods
Study Design and Oversight
The DOVE trial was a phase 3 double-blind, pla-
cebo-controlled, parallel-group, multinational trial 
designed to assess the efficacy of prasugrel in 
reducing the rate of vaso-occlusive crisis, a com-
posite end point of painful crisis or acute chest 
syndrome, in children and adolescents with sickle 
cell anemia. The design of the trial has been de-
scribed previously.20
The protocol and steering committees, which 
were made up of academic investigators and 
representatives of the sponsors (Daiichi Sankyo 
and Eli Lilly), designed the study and supervised 
its conduct (a complete list of the members of 
each committee is provided in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org). In each country, the study 
was approved by national regulatory authorities 
and by local ethics committees, institutional re-
view boards, or both and abided by local regula-
tions. Periodic safety assessments were conducted 
by an independent external data and safety moni-
toring committee. The principal investigators had 
full access to the data, and the data analyses were 
independently verified by the Harvard Clinical 
Research Institute for both accuracy and adher-
ence to the protocol and to the approved statisti-
cal analysis plan, which are available at NEJM.org.
Study Population
The study population included children and ado-
lescents, 2 through 17 years of age, who had sickle 
cell anemia (homozygous hemoglobin S [HbSS] 
or hemoglobin Sβ0 thalassemia) and who had 
had two or more vaso-occlusive crises during the 
previous year. The definition of vaso-occlusive 
crisis that we used to assess eligibility for inclu-
sion in the trial was identical to that used for the 
primary end point. Details of the inclusion and 
exclusion criteria20 are provided in Table S1 in 
the Supplementary Appendix. Information on race 
and ethnic background was reported by the pa-
tient or the patient’s family. Participants from 51 
sites in 13 countries underwent randomization. 
Patients who were being treated with hydroxy-
urea at a dose that had been stable for more than 
60 days before screening were eligible to par-
ticipate. Transcranial Doppler ultrasonographic 
screening for primary stroke risk was required to 
have been performed within the preceding year 
in all patients 2 through 16 years of age. The 
eligibility criteria were intended to identify the 
patients with the greatest potential for benefit 
from prasugrel while minimizing the risk of bleed-
ing or stroke. Therefore, in accordance with evi-
dence-based consensus guidelines for sickle cell 
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disease, the exclusion criteria included an abnor-
mal or conditional result of transcranial Doppler 
ultrasonography within the preceding year; cur-
rent or past regular red-cell transfusions for 
stroke prevention; a history of transient ischemic 
attack, stroke, or head trauma; regular treatment 
with an antiplatelet agent, anticoagulant, or non-
steroidal antiinflammatory drug; and clinical find-
ings associated with an increased risk of bleed-
ing.21 The child’s parent or legal representative 
provided written informed consent. The participat-
ing children also gave documented assent, as re-
quired under local regulations.
Randomization and Study Procedures
The study included a 2-week screening period fol-
lowed by a double-blind period during which the 
participant took prasugrel or placebo (treatment 
period), a period that was planned to last a mini-
mum of 9 months and a maximum of 24 months; 
this allowed participants who enrolled early to 
participate for a longer time. Participants were 
randomly assigned, in a 1:1 ratio, with the use 
of an interactive voice-response system, to receive 
either oral prasugrel or placebo; assignments 
were balanced according to receipt or no receipt 
of hydroxyurea treatment, country, and age group 
(2 through 5, 6 through 11, and 12 through 17 
years of age) on the basis of a minimization al-
gorithm.22 Prasugrel treatment was initiated at a 
dose of 0.08 mg per kilogram of body weight; 
with the use of an individualized dose-adjust-
ment strategy, the treatment was then adjusted 
to a dose between 0.04 mg per kilogram and 
0.12 mg per kilogram (maximum absolute dose, 
10 mg) that provided a targeted level of platelet 
reactivity.20 The placebo was identical in appear-
ance to prasugrel, and the dose of placebo was 
mock-adjusted in the same manner as the dose 
of prasugrel.20
Platelet reactivity was measured with the use 
of the VerifyNow P2Y12 assay, a whole-blood point-
of-care assay that reports ADP-induced platelet 
aggregation results as P2Y12 reaction units (PRUs) 
and percentage inhibition. A target range of 231 
to 136 PRUs (30 to 60% inhibition) was chosen 
on the basis of previous studies of prasugrel in-
volving patients with sickle cell anemia, as well 
as studies of clopidogrel involving infants with 
congenital heart disease who were found to have 
no increased risk of bleeding in association with 
similar levels of inhibition after treatment.23,24 
After the 45-day dose-adjustment period, partici-
pants returned for follow-up visits every 3 months, 
with dose adjustments made according to chang-
es in body weight.20 Adherence was monitored by 
direct questioning and by pill counts conducted 
at each visit. Participants were considered to be 
adherent if they took 80 to 120% of the assigned 
regimen (study drug or placebo).
A handheld, mobile, electronic patient-report-
ed outcome (ePRO) device was used to alert the 
patients and caregivers to record information on 
several of the secondary end points.20,25-27 Care-
givers of participants 4 years of age or older or 
the participants themselves completed this ePRO 
pain diary daily during the 2-week screening 
period and for the first 9 months of the double-
blind treatment period.
End Points
The primary end point was the rate of vaso-
occlusive crisis, which was a composite of pain-
ful crisis or acute chest syndrome. A painful 
crisis was defined as the onset of moderate-to-
severe pain that lasted for at least 2 hours, for 
which there was no explanation other than 
sickle cell disease and that required therapy with 
oral or parenteral opioids, ketorolac, or other 
analgesics prescribed by a health care provider 
in a medical setting, such as a hospital, clinic, or 
emergency department, or in the context of docu-
mented telephone management.3,20,28,29 Acute 
chest syndrome was defined as acute illness 
characterized by fever, respiratory symptoms, or 
both, accompanied by a new pulmonary infil-
trate on chest radiography. Vaso-occlusive crisis 
end points meeting these definitions required 
documentation, which included completion by a 
medical professional of a trial-specific telephone 
management tool when applicable. Events that 
recurred within 7 days of each other were con-
sidered to be a single episode.30,31
The major secondary end points were the 
diary-documented rate and intensity of sickle cell–
related pain, with intensity assessed on a scale 
of 0 to 10 with the use of a modified version of 
the Faces Pain Scale–Revised (in which 0 denotes 
no pain and 10 denotes the worst pain possible)20; 
the rates of hospitalization for vaso-occlusive cri-
sis, painful crisis, and acute chest syndrome; the 
rate of sickle cell–related red-cell transfusion; and 
the diary-documented rate of analgesic use and 
school attendance. Safety assessments included 
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the incidence of hemorrhagic events requiring 
medical intervention, the incidence of hemorrhagic 
and nonhemorrhagic adverse events that occurred 
while the participant was taking the study drug or 
placebo, and the rate of permanent discontinua-
tion of the study drug or placebo owing to hem-
orrhagic and nonhemorrhagic adverse events.
Statistical Analysis
We estimated that 220 patients would need to be 
enrolled for the study to have approximately 85% 
power to detect a 35% lower rate of vaso-occlu-
sive crisis in the prasugrel group than in the 
placebo group, with the use of a two-sided test 
at a significance level of 0.05, as analyzed with 
the Andersen–Gill model, which is an extension 
of the Cox proportional-hazards model for the 
analysis of recurrent events. Although the sam-
ple size for the safety analysis was not formally 
assessed, we planned to have at least 204 pa-
tients completing at least 9 months of treatment. 
All efficacy analyses were performed with data 
from the intention-to-treat population, and safe-
ty analyses were performed with data from pa-
tients who received at least one dose of the as-
signed regimen (study drug or placebo).
The time to a recurrent episode of vaso-occlu-
sive crisis was analyzed with the use of the An-
dersen–Gill model. A robust variance estimate 
was used, with treatment, hydroxyurea use, and 
age group included as factors in the model. The 
major secondary efficacy end points were also 
analyzed with the use of the Andersen–Gill 
model. The pain-diary end points were computed 
and analyzed by means of a mixed-effects mod-
el repeated-measures analysis. The mixed-effects 
model included the fixed effects of treatment, 
the baseline value of the pain-diary measure, hy-
droxyurea use, age group, time, and treatment-by-
time interaction. A covariance-structure selection 
process was used to determine the best-fit covari-
ance structure for the estimation of within-patient 
variability.
If a significant reduction in the primary end 
point was achieved, a fixed-sequence gatekeeping 
testing strategy for the major secondary efficacy end 
points was planned to control the overall type I error 
rate.20 We also explored the consistency of the treat-
ment effect on the primary and key secondary 
efficacy end points in prespecified subgroups. A 
prespecified landmark analysis of the primary 
efficacy end point was performed with the use 
of a time-dependent Andersen–Gill model to 
estimate the rate ratios before and after 6 months, 
9 months, and 12 months across all age groups.
R esult s
Enrollment and Follow-up
The randomization and follow-up of participants, 
including a breakdown according to age group, 
are shown in Figure S1 in the Supplementary 
Appendix. From May 2013 through June 2015, a 
total of 341 patients underwent randomization 
at 51 sites in 13 countries, with 171 assigned to 
the prasugrel group and 170 assigned to the pla-
cebo group. A total of 275 participants completed 
the 9-month follow-up visit; of these, 9 partici-
pants discontinued the assigned regimen after 
the 9-month visit, and 2 participants completed 
24 months of the assigned regimen before the 
database lock. The remaining 264 patients were 
continuing their participation in the study at the 
time of the database lock. Because the youngest 
age group was the slowest to enroll, fewer par-
ticipants in this age group than in the older age 
groups had reached the 9-month visit at the time 
of the database lock. The duration of study fol-
low-up was similar in the two study groups (me-
dian, 303 days in the prasugrel group and 306 days 
in the placebo group). No participants were lost 
to follow-up.
The percentage of participants who were ad-
herent to the assigned regimen was similar in 
the two study groups (78.2% of participants in 
the prasugrel group and 81.2% of participants in 
the placebo group, P = 0.59). Diary data from 268 
patients 4 years of age or older were collected for 
up to 9 months.
Baseline Characteristics of Participants
The demographic and baseline clinical characteris-
tics of the participants are shown in Table 1. Dis-
tributions of age, sex, weight, and hydroxyurea use 
were similar in the two groups. Of the 341 pa-
tients who underwent randomization, 308 (90.3%) 
had HbSS sickle cell disease, and 153 (44.9%) were 
receiving hydroxyurea.
End Points
Vaso-Occlusive Crisis Events
A total of 736 vaso-occlusive crisis events occurred 
during the study: 328 events among 115 patients 
(67.3%) in the prasugrel group and 408 events 
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among 123 patients (72.4%) in the placebo group. 
The rate of vaso-occlusive crisis events (the num-
ber per person-year) was somewhat lower, but 
not significantly so, in the prasugrel group than 
in the placebo group: 2.30 events per person-year 
and 2.77 events per person-year, respectively (rate 
ratio, 0.83; 95% confidence interval [CI], 0.66 to 
1.05; P = 0.12) (Table 2 and Fig. 1).
In the landmark analyses, the rate ratio of 
vaso-occlusive crisis through 9 months was 0.88 
(95% CI, 0.69 to 1.12); after 9 months, the rate 
ratio decreased to 0.63 (95% CI, 0.42 to 0.94), 
but the difference in rate ratios between these 
periods was not significant (P = 0.09 for interac-
tion) (Table S2 in the Supplementary Appendix). 
The rate ratio continued to decrease numerically 
at 12 months, but only 26% of the participants 
(88 of 341) reached 12 months of treatment.
Subgroup Analyses
The results of the subgroup analyses are shown 
in Figure 2. Although the effect of prasugrel on 
vaso-occlusive crises was greatest in the group 
of participants who were 12 through 17 years of 
age (P = 0.06) and in patients who were not receiv-
ing hydroxyurea (P = 0.06), no significant interac-
tion was observed between the study groups with 
regard to any of the characteristics of patients.
Secondary End Points
Prasugrel had no significant effect on the rate of 
hospitalization for vaso-occlusive crises, the rate 
of red-cell transfusion, the rate of pain, the in-
tensity of pain, the rate of analgesic use, or the 
rate of absence from school owing to sickle cell–
related pain, as assessed with the use of daily 
pain diaries (Table 2). Treatment with prasugrel 
had no significant effect on other secondary end 
points, including the duration of hospitalization 
for vaso-occlusive crises, the time from random-
ization to the first or second vaso-occlusive crisis, 
and the incidence of transient ischemic attack or 
ischemic stroke. After adjustment to the final 
maintenance dose of the study drug or placebo, 
platelet reactivity was lower in the prasugrel 
group than in the placebo group (mean difference, 
−72.4 PRUs; 95% CI, −83.7 to −61.1; P<0.001).
Safety and Adverse Events
There was no significant difference between the 
study groups in the incidence of hemorrhagic 
events requiring medical intervention, in the 
incidence of hemorrhagic and nonhemorrhagic 
adverse events that occurred during the treat-
ment period (Table 3, and Table S3 in the Sup-
plementary Appendix), or in the side-effect pro-
file of the study drug when administered with or 
without hydroxyurea (Table S4 in the Supplemen-
tary Appendix). There were three deaths during 
the treatment period, two in the placebo group 
and one in the prasugrel group; none were judged 
by the investigator as being related to the study 
drug or placebo. In the prasugrel group, the death 
was due to a ruptured intracerebral aneurysm 
and cerebral hemorrhage.
Discussion
In this phase 3 multinational, placebo-con-
trolled trial evaluating the efficacy of prasugrel 
Characteristic
Placebo Group 
(N = 170)
Prasugrel Group 
(N = 171)
Age — yr 10.6±4.3 10.6±4.3
Age group — no. (%)
2 through 5 yr 33 (19.4) 34 (19.9)
6 through 11 yr 66 (38.8) 66 (38.6)
12 through 17 yr 70 (41.2) 71 (41.5)
18 yr 1 (0.6) 0
Hydroxyurea use — no. (%) 76 (44.7) 77 (45.0)
Female sex — no. (%) 86 (50.6) 87 (50.9)
Weight — kg 31.9±14.8 33.2±15.4
Body-mass index 16.5±2.8 17.1±3.6
Race — no./total no. (%)†
White 58/169 (34.3) 58/171 (33.9)
Black 109/169 (64.5) 113/171 (66.1)
Multiple 2/169 (1.2) 0
Location of enrollment — no. (%)
Ghana or Kenya 72 (42.4) 76 (44.4)
Egypt, Lebanon, or Turkey 52 (30.6) 51 (29.8)
United States or Canada 29 (17.1) 27 (15.8)
Brazil 0 1 (0.6)
Saudi Arabia or Oman 4 (2.4) 3 (1.8)
Belgium, Italy, or United Kingdom 13 (7.6) 13 (7.6)
Vaso-occlusive crises in previous year — no. 4.0±7.9 3.5±2.0
*  Plus–minus values are means ±SD. Body-mass index, the weight in kilograms 
divided by the square of the height in meters, was the only characteristic that 
differed significantly between the study groups (P = 0.04).
†  Race was self-reported.
Table 1. Characteristics of the Participants at Baseline.*
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End Point
Placebo Group 
(N = 170)
Prasugrel Group 
(N = 171) Rate Ratio (95% CI) P Value
Vaso-occlusive crisis
Patients with events — no. (%) 123 (72.4) 115 (67.3)
Total events 408 328
Length of follow-up — patient-yr 147.44 142.89
Event rate per patient-yr 2.77 2.30 0.83 (0.66 to 1.05) 0.12
Painful crisis
Patients with events — no. (%) 122 (71.8) 113 (66.1)
Total events 401 320
Length of follow-up — patient-yr 147.44 142.89
Event rate per patient-yr 2.72 2.24 0.82 (0.65 to 1.04) 0.11
Acute chest syndrome
Patients with events — no. (%) 15 (8.8) 15 (8.8)
Total events 17 16
Length of follow-up — patient-yr 147.44 142.89
Event rate per patient-yr 0.12 0.11 0.96 (0.48 to 1.93) 0.92
Hospitalization for vaso-occlusive crisis
Patients with events — no. (%) 76 (44.7) 69 (40.4)
Total events 166 152
Length of follow-up — patient-yr 147.44 142.89
Event rate per patient-yr 1.13 1.06 0.94 (0.65 to 1.37) 0.76
Red-cell transfusions due to sickle cell disease
Patients with events — no. (%) 37 (21.8) 37 (21.6)
Total events 62 71
Length of follow-up — patient-yr 147.44 142.89
Event rate per patient-yr 0.42 0.50 1.17 (0.71 to 1.91) 0.54
Least-Squares Mean 
Difference (95% CI)
Least-squares mean monthly rate of daily pain — %* 17.7 17.5 −0.24 (−4.6 to 4.1) 0.91
Least-squares mean monthly intensity of daily pain* 0.61 0.71 0.10 (−0.11 to 0.31) 0.37
Least-squares mean monthly rate of analgesic use — %† 22.8 24.3 1.51 (−4.19 to 7.21) 0.60
Least-squares mean quarterly rate of absence from school — %† 10.3 11.5 1.27 (−2.11 to 4.65) 0.46
Platelet reactivity — PRU‡
Baseline 276 276 0.19 (−10.1 to 10.5) 0.97
Fully adjusted dose 275 203 −72.4 (−83.7 to −61.1) <0.001
At 9 months 281 214 −66.9 (−79.6 to −54.2) <0.001
*  The rate and mean intensity of daily pain were evaluated only for patients 7 years of age or older; data were available for 127 participants in 
the placebo group and for 127 participants in the prasugrel group. The rate of daily pain is the percentage of days during the course of a 
month during which a patient experienced pain. Pain intensity was assessed on a scale of 0 to 10 with the use of a modified version of the 
Faces Pain Scale–Revised (in which 0 denotes no pain and 10 denotes the worst pain possible).
†  The rates of analgesic use and school absence were evaluated only for patients 4 years of age or older. For the rate of analgesic use, data 
were available for 153 participants in the placebo group and 153 participants in the prasugrel group; for the rate of absence from school, 
data were available for 115 participants in the placebo group and for 105 participants in the prasugrel group
‡  Platelet reactivity was measured with an assay that reports adenosine diphosphate–induced platelet aggregation results as P2Y12 reaction 
units (PRUs). Values for the fully adjusted dose and at 9 months were not adjusted for the baseline value. Data were available for 163 partic-
ipants in the placebo group and for 161 participants in the prasugrel group.
Table 2. Primary and Secondary Efficacy End Points.
Figure 1 (facing page). Mean Number of Vaso-Occlusive Crises.
The data at each time point are the estimated mean number of events that occurred in the patient population up to that point. In each 
panel, the vertical dashed line represents 9 months (270 days) after randomization. Because of the declining numbers of patients at risk, 
the mean cumulative function plots were truncated at 76 weeks.
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in children and adolescents with sickle cell ane-
mia, the primary end point — the rate of vaso-
occlusive crisis — did not differ significantly 
between the prasugrel group and the placebo 
group. In addition, prasugrel treatment had no 
significant effect on any of the prespecified sec-
ondary end points. These results suggest that 
treatment with prasugrel alone, at the levels of 
platelet inhibition attained in this study, is not 
effective in significantly reducing the frequency 
of acute vaso-occlusive crises in children 2 
through 17 years of age who have sickle cell 
anemia. The overall rate of hemorrhagic and 
nonhemorrhagic adverse events — including 
deaths, serious adverse events, adverse events 
leading to discontinuation of the study drug or 
placebo, adverse events that occurred during the 
treatment period, and adverse events that were 
judged as being possibly related to the study 
drug or placebo or to the study procedure — did 
not differ significantly between the study 
groups.
Sickle cell anemia is a heterogeneous and 
complex disease in which platelet activation is 
only one of several mechanisms of vascular in-
jury, which perhaps explains why prasugrel was 
ineffective. This result is consistent with those 
of previous trials of other agents directed at a 
single pathologic process, in which treatment 
has generally failed.6 However, the nonsignifi-
cant effect of prasugrel in the oldest age group 
may suggest that platelet activation is relatively 
more important in these older patients, a hypoth-
esis that is consistent with the fact that endothe-
Figure 2. Rates of Vaso-Occlusive Crises According to Demographic Group.
The Africa subgroup includes Ghana and Kenya; the Americas subgroup includes Brazil, the United States, and Canada; the Middle East 
and Turkey subgroup includes Saudi Arabia, Oman, Egypt, Lebanon, and Turkey; and the western Europe subgroup includes Belgium, 
 Italy, and the United Kingdom. A body-mass index (the weight in kilograms divided by the square of the height in meters) of 15.8, the 
median among participants at baseline, was used as the cutoff for the subgroups based on this characteristic. None of the results of the 
subgroup analyses were significant. HbSβ0 denotes hemoglobin Sβ0 thalassemia, and HbSS homozygous hemoglobin S.
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lial dysfunction in sickle cell disease is progres-
sive.1,31-33 The results in the oldest subgroup 
(Fig. 1D) were largely responsible for the separa-
tion of the treatment and placebo curves that 
was observed at 3 months (Fig. 1A), whereas 
little treatment effect was observed in the two 
younger subgroups (Fig. 1B and 1C). Event rates 
were similar in the two younger age groups, al-
though relatively few participants in the young-
est age group had completed 9 months of treat-
ment, which limited the interpretation of the 
results in this age group. In this intercontinental 
study, we succeeded in enrolling patients with 
sickle cell anemia who were from various re-
gions worldwide. Although no significant differ-
ences in the rates of vaso-occlusive crisis were seen 
between treatment groups according to geographic 
region, it is possible that randomization did not 
completely eliminate bias related to disease het-
erogeneity (e.g., beta globin haplotype), environ-
mental factors, or coexisting conditions (e.g., ma-
laria), and cross-cultural differences may have 
influenced the results.
We found no synergistic effect between hy-
droxyurea and prasugrel, and in fact prasugrel 
seemed to be less effective in participants who 
were also receiving hydroxyurea (Fig. 2). This is 
perhaps surprising, but it suggests that anti-
platelet agents may have a role in the treatment 
of patients in whom hydroxyurea therapy has 
failed. It is difficult to further analyze any inter-
action between hydroxyurea and prasugrel, be-
cause we did not specifically collect information 
on responses to hydroxyurea. Although data on 
routine complete blood counts were collected for 
safety assessments and revealed no significant 
safety concerns, blood counts have not been used 
to assess adherence to hydroxyurea therapy. There 
was no a priori reason to believe that levels of 
hemoglobin F would modify the response to pra-
sugrel. Future studies of adherence and response 
to hydroxyurea in which hemoglobin F levels are 
measured may make it possible to accurately as-
sess the effect of hydroxyurea in combination 
with prasugrel. Similarly, sickle cell anemia is a 
highly variable condition; more detailed labora-
tory information, such as hemoglobin F levels and 
alpha globin genotype, may allow better identifica-
tion of the patients who are most likely to have 
a response to treatment. It should be noted that 
hydroxyurea-treated patients who were receiving 
prasugrel had no more adverse events than did 
those who were not receiving prasugrel.
No new safety issues were identified in as-
Adverse Event
Placebo Group 
(N = 170)
Prasugrel Group 
(N = 170)† P Value
no. of patients (%)
Hemorrhagic adverse events
Hemorrhagic events requiring medical intervention 8 (4.7) 11 (6.5) 0.64
Discontinuation of study drug or placebo because of 
an adverse event
1 (0.6) 2 (1.2) 0.99
Adverse event during treatment period 33 (19.4) 32 (18.8) 0.99
Death 0 1 (0.6) 0.99
Serious adverse event 3 (1.8) 5 (2.9) 0.72
Nonhemorrhagic adverse events
Discontinuation of study drug or placebo because of 
an adverse event
4 (2.4) 4 (2.4) 0.99
Adverse event during treatment period 162 (95.3) 157 (92.4) 0.37
Death 2 (1.2)‡ 0 0.50
Serious adverse event 96 (56.5) 87 (51.2) 0.38
*  Adverse events included events that occurred from the first dose until 10 days after the last dose of the study drug or 
placebo. A patient could have more than one event, and each patient could have both nonhemorrhagic and hemorrhag-
ic events and be counted in both categories.
†  One patient did not receive the study drug after randomization and was not included in the safety analyses.
‡  One of the two deaths in the placebo group was reported after the database lock.
Table 3. Adverse Events.*
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sociation with prasugrel treatment in this popu-
lation. The single death in the prasugrel group 
was from an intracerebral hemorrhage. A post-
mortem examination revealed a ruptured cere-
bral aneurysm, and the death was not consid-
ered by the investigator to be treatment-related. 
The participant had had normal results of tran-
scranial Doppler ultrasonography at study entry 
and no previous neuroimaging or clinical his-
tory of neurologic symptoms.
Because safety was a priority in this study, we 
aimed for modest platelet inhibition and chose a 
narrower target range (231 to 136 PRUs, corre-
sponding to 30 to 60% platelet inhibition) than the 
range used in studies of adults with acute coronary 
syndrome (235 to 95 PRUs).34 The lack of effect of 
the administered dose of prasugrel may be related 
to the fact that the effect on platelet inhibition was 
smaller than had been anticipated. An adjustment 
of the dose to a lower PRU limit (i.e., greater plate-
let inhibition) may have offered therapeutic ben-
efit but potentially would have been associated 
with an increased risk of bleeding.
In summary, in our study, the rate of vaso-
occlusive crises was not significantly lower with 
prasugrel than with placebo among children 
with sickle cell anemia, although the smaller 
number of vaso-occlusive crises in the prasugrel 
group, particularly among the older children, is 
encouraging. Antiplatelet agents, such as prasu-
grel, may have a therapeutic role as part of a 
multidrug approach targeting multiple aspects 
of the complex pathophysiological mechanisms 
of sickle cell anemia. The DOVE trial included 
patients in Africa and the Middle East, where 
sickle cell anemia is most prevalent. The suc-
cessful completion of the DOVE trial provides 
guidance for future multicontinental clinical 
trials of treatment for sickle cell anemia.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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